AEON Biopharma, Inc. (AEON) - Dilution Analysis

10-Q filing | 26.3M shares outstanding

10-K filing | 25.3M shares outstanding

8-K filing: AEON Biopharma issued 11,918,380 shares of common stock and 11,236,631 pre-funded warrants, a new senior secured convertible note in a principal amount of $1,500,000, and warrants to purchase up to 8,000,000 shares of Common Stock at an exercise price of $1.09392 per share to Daewoong Pharmaceutical Co., LTD. in exchange for Old Notes.

8-K filing: AEON Biopharma Inc. enters into an Exchange Agreement with Daewoong Pharmaceuticals to exchange convertible notes for common stock, pre-funded warrants, a new convertible note, and common stock warrants, subject to stockholder approval.

10-Q filing | 11.6M shares outstanding

10-Q filing | 1.2M shares outstanding

10-Q filing | 11.3M shares outstanding

10-K filing | 0.5M shares outstanding

8-K filing: Stock split 1-for-72 | Outstanding: 79,970,693 → 1

8-K filing: AEON Biopharma, Inc. closed an underwritten public offering of 40,000,000 Common Units and Aegis exercised its over-allotment option with respect to 6,000,000 Series A Warrants and 6,000,000 Series B Warrants, with the company receiving net proceeds of approximately $18.3 million. ($18.3M proceeds)

10-Q filing | 39.5M shares outstanding

S-3 filing: AEON Biopharma, Inc. is offering up to $200,000,000 in the aggregate of Class A Common Stock, Preferred Stock, Warrants, Purchase Contracts, and Units from time to time in one or more offerings.

10-Q filing | 38.8M shares outstanding

S-1/A filing: This S-1/A filing registers for resale shares of common stock and warrants by selling security holders, as well as shares issuable upon exercise of warrants and options or settlement of restricted stock units.

S-1/A filing: This S-1/A filing relates to the resale of common stock and private placement warrants of AEON Biopharma, Inc. by registered holders, as well as the issuance of common stock upon exercise of warrants and options.

10-Q filing | 37.3M shares outstanding

S-1/A filing: AEON Biopharma, Inc. is filing an S-1/A to register the resale of common stock and warrants by selling security holders.

10-K filing | 37.2M shares outstanding

8-K filing: AEON Biopharma, Inc. entered into a subscription agreement with Daewoong Pharmaceutical Co., LTD. for the sale and issuance of senior secured convertible notes in the principal amount of up to $15.0 million, convertible into Class A common stock.

S-1/A filing: This S-1/A filing registers for resale shares of Common Stock and Warrants held by Registered Holders, as well as shares issuable upon exercise of warrants and options or settlement of restricted stock units.

10-Q filing | 37.2M shares outstanding

S-1/A filing: This S-1/A filing registers for resale (i) 20,177,178 shares of Class A common stock issued in connection with the Business Combination, (ii) 1,075,000 shares of Common Stock issued pursuant to the New Money PIPE Subscription Agreements, (iii) 6,275,000 shares of Common Stock issued pursuant to the FPA Funding Amount PIPE Subscription Agreements, (iv) up to 988,764 shares of Common Stock issuable pursuant to the FPA Funding Amount PIPE Subscription Agreements, (v) 1,000 shares of Common Stock issued pursuant to the Round Lot Holder Subscription Agreements, (vi) up to 4,013,282 shares of Common Stock reserved for issuance upon the exercise of options to purchase shares of Common Stock or settlement of restricted stock unit awards into shares of Common Stock, (vii) up to 374,628 shares of Common Stock reserved for issuance upon the exercise of options to purchase shares of Common Stock or settlement of restricted stock unit awards into shares of Common Stock, and (viii) up to 14,479,999 shares of Common Stock upon the exercise of outstanding warrants; and (ix) the resale of up to 5,279,999 warrants.

S-1 filing: AEON Biopharma, Inc. is filing an S-1 to register the resale of shares of Class A common stock and warrants by certain securityholders, as well as the issuance of shares of common stock upon exercise of warrants and options.

8-K filing: AEON's Amended and Restated Certificate of Incorporation became effective on July 21, 2023, and the Board approved and adopted the Amended and Restated Bylaws of AEON, effective immediately prior to the completion of the Business Combination; AEON also adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors, and may issue additional shares to ACM ASOF VIII Secondary-C LP and Polar if the Transfer VWAP for Transferred PIPE Shares is less than $7.00 per share.

10-Q filing | 2.0M shares outstanding

8-K filing: Priveterra's public stockholders holding 1,681,348 shares of Class A common stock validly elected to redeem their public shares for a full pro rata portion of the trust account holding the proceeds from Priveterra's initial public offering.

8-K filing: Priveterra Acquisition Corp. entered into Forward Purchase Agreements with ACM ARRT J LLC and Polar Multi-Strategy Master Fund for OTC Equity Prepaid Forward Transactions, and also entered into PIPE Subscription Agreements with various investors for the purchase of Priveterra Common Stock at $7.00 per share. ($7.0M proceeds)

10-Q filing | 2.0M shares outstanding

10-K filing | 6.9M shares outstanding

8-K filing: Priveterra Acquisition Corp. entered into a business combination agreement with Priveterra Merger Sub, Inc. and AEON Biopharma, Inc., where Merger Sub will merge with and into AEON, with AEON surviving as a wholly owned subsidiary of Priveterra Acquisition Corp.

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.9M shares outstanding

10-K filing | 6.9M shares outstanding

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.9M shares outstanding

10-Q filing | 6.9M shares outstanding

8-K filing: Priveterra Acquisition Corp. consummated its initial public offering of 27,600,000 units at $10.00 per unit, generating gross proceeds of $276,000,000, and completed a private placement of 5,213,333 warrants to Priveterra Sponsor, LLC at $1.50 per warrant, generating gross proceeds of $7,820,000. ($283.82M proceeds)

8-K filing: Priveterra Acquisition Corp. consummated its initial public offering of 27,600,000 Units at $10.00 per Unit, generating gross proceeds of $276,000,000, and simultaneously completed the private sale of 5,213,333 warrants to Priveterra Sponsor, LLC at $1.50 per warrant, generating gross proceeds of $7,820,000. ($283.82M proceeds)

S-1/A filing: This is an S-1/A filing detailing other expenses of issuance and distribution, as well as indemnification of directors and officers.

S-1 filing: Priveterra Acquisition Corp. is offering 20,000,000 units at $10.00 per unit, with each unit consisting of one share of Class A common stock and one-third of one redeemable warrant.